The Renoprotective Effects of Desflurane And Sevoflurane in Lower Limb Ischemia-Reperfusion Injury on Streptozotocin-Induced Diabetic Rats

Abstract

Aim: The study aims to determine the protective effects of sevoflurane and desflurane on the kidneys in lower limb ischemia-reperfusion injury (IRI) streptozotocin-induced diabetic rats. Method: Thirty Wistar rats were randomly divided into equal five groups. The control (group C), diabetes-control (group DC), Diabetes-I/R (group DIR), Diabetes-I/R-sevoflurane (group DIRS), Diabetes-I/R-desflurane (group DIRD). 55 mg/kg Streptozotocin was administered intraperitoneally to diabetic groups as a single dose. 72nd hours were considered diabetic blood glucose 250 mg/dl or above, and at the end of 4 weeks, all groups underwent laparotomy. In groups C and DC, there was no further action. In the group, DIR was performed 2 hours in the infrarenal abdominal aorta in order clamped be put and remove. Sevoflurane and desflurane were administered so that the minimum alveolar concentration was one during the ischemia and reperfusion periods. At the end of the reperfusion period, kidney tissues were taken for biochemical and histopathological examinations. Results: In the DIR group, Nitric oxide synthases (NOS) enzyme activity was observed significantly higher than C and DC groups. In DIRS and DIRD groups, it was significantly lower than DIR. TBARS level is significantly higher in all groups compared to group C. In the DIR group, it was significantly higher than in the DC group. In DIRS and DIRD groups, it was significantly lower than DIR. DIR group Superoxide dismutase (SOD) enzyme activity was observed significantly higher than C and DC groups. In DIRS and DIRD groups, it was significantly lower than DIR. Conclusion: These results demonstrate that sevoflurane and desflurane have protective effects on the kidneys in lower limb IRI on streptozotocin-induced diabetic rats.

Keywords

• Ischemia-reperfusion
• sevoflurane
• desflurane
• kidney

References

1. 1. Wei H, Dong TL, Yang XH. [Effect of penehyclidine hydrochloride injection on pulmonary ischemia-reperfusion in aortic dissection surgery]. Zhonghua Yi Xue Za Zhi 2018; 98:777-780.
2. 2. Budic I, Pavlovic D, Kitic D et al. Tourniquet-induced ischemia-reperfusion injuries during extremity surgery at children's age: impact of anesthetic chemical structure. Redox Rep 2013; 18:20-26.
3. 3. Cowled P, Fitridge R. Pathophysiology of Reperfusion Injury. In Fitridge R, Thompson M (editors): Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists. Adelaide (AU): University of Adelaide Press © The Contributors 2011.; 2011.
4. 4. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357:1121-1135.
5. 5. Saran R, Robinson B, Abbott KC et al. US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States. Am J Kidney Dis 2017; 69:A7-a8.
6. 6. Hertzberg D, Sartipy U, Holzmann MJ. Type 1 and type 2 diabetes mellitus and risk of acute kidney injury after coronary artery bypass grafting. Am Heart J 2015; 170:895-902.
7. 7. Venot M, Weis L, Clec'h C et al. Acute Kidney Injury in Severe Sepsis and Septic Shock in Patients with and without Diabetes Mellitus: A Multicenter Study. PLoS One 2015; 10:e0127411.
8. 8. Girman CJ, Kou TD, Brodovicz K et al. Risk of acute renal failure in patients with Type 2 diabetes mellitus. Diabet Med 2012; 29:614-621.

9. 9. Gong DJ, Wang L, Yang YY, Zhang JJ, Liu XH. Diabetes aggravates renal ischemia and reperfusion injury in rats by exacerbating oxidative stress, inflammation, and apoptosis. Ren Fail 2019; 41:750-761.
10. 10. Zhao H, Watts HR, Chong M et al. Xenon treatment protects against cold ischemia associated delayed graft function and prolongs graft survival in rats. Am J Transplant 2013; 13:2006-2018.
11. 11. Tuuminen R, Nykänen AI, Saharinen P et al. Donor simvastatin treatment prevents ischemia-reperfusion and acute kidney injury by preserving microvascular barrier function. Am J Transplant 2013; 13:2019-2034.
12. 12. Talab SS, Emami H, Elmi A et al. Chronic lithium treatment protects the rat kidney against ischemia/reperfusion injury: the role of nitric oxide and cyclooxygenase pathways. Eur J Pharmacol 2010; 647:171-177.
13. 13. Erbatur ME, Sezen Ş C, Bayraktar AC, Arslan M, Kavutçu M, Aydın ME. Effects of dexmedetomidine on renal tissue after lower limb ischemia reperfusion injury in streptozotocin induced diabetic rats. Libyan J Med 2017; 12:1270021.
14. 14. Kim M, Ham A, Kim JY, Brown KM, D'Agati VD, Lee HT. The volatile anesthetic isoflurane induces ecto-5'-nucleotidase (CD73) to protect against renal ischemia and reperfusion injury. Kidney Int 2013; 84:90-103.
15. 15. Arslan M, Comu FM, Isik B, Ozturk L, Kesimci E. Effect of dexmedetomidine on erythrocyte deformability during ischemia-reperfusion injury of liver in diabetic rats. Bratisl Lek Listy 2012; 113:687-691.
16. 16. Bostan H, Kalkan Y, Tomak Y et al. Reversal of rocuronium-induced neuromuscular block with sugammadex and resulting histopathological effects in rat kidneys. Ren Fail 2011; 33:1019-1024.
17. 17. Durak I, Canbolat O, Kavutçu M, Oztürk HS, Yurtarslani Z. Activities of total, cytoplasmic, and mitochondrial superoxide dismutase enzymes in sera and pleural fluids from patients with lung cancer. J Clin Lab Anal 1996; 10:17-20.
18. 18. Aebi H. Catalase Estimation. In Bergmeyer H (editor): Methods of Enzymatic Analysis: Academic Press; 1974, pp. 673-677.
19. 19. Durak I, Kavutcu M, Kaçmaz M et al. Effects of isoflurane on nitric oxide metabolism and oxidant status of guinea pig myocardium. Acta Anaesthesiol Scand 2001; 45:119-122.
20. 20. Van Ye TM, Roza AM, Pieper GM, Henderson J, Jr., Johnson CP, Adams MB. Inhibition of intestinal lipid peroxidation does not minimize morphologic damage. J Surg Res 1993; 55:553-558.
21. 21. Jang HR, Rabb H. The innate immune response in ischemic acute kidney injury. Clin Immunol 2009; 130:41-50.
22. 22. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat Rev Nephrol 2011; 7:189-200.
23. 23. Kellum JA, Unruh ML, Murugan R. Acute kidney injury. BMJ Clin Evid 2011; 2011.
24. 24. Hoste EA, Clermont G, Kersten A et al. RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. Crit Care 2006; 10:R73.
25. 25. Mehta RL, Cerdá J, Burdmann EA et al. International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 2015; 385:2616-2643.
26. 26. Yang JC, Lin MW, Rau CS et al. Altered exosomal protein expression in the serum of NF-κB knockout mice following skeletal muscle ischemia-reperfusion injury. J Biomed Sci 2015; 22:40.
27. 27. Basel H, Kavak S, Demir H, Meral I, Ekim H, Bektas H. Effect of levosimendan injection on oxidative stress of rat myocardium. Toxicol Ind Health 2013; 29:435-440.
28. 28. Vázquez-Medina JP, Zenteno-Savín T, Elsner R. Antioxidant enzymes in ringed seal tissues: potential protection against dive-associated ischemia/reperfusion. Comp Biochem Physiol C Toxicol Pharmacol 2006; 142:198-204.
29. 29. Baltalarli A, Ozcan V, Bir F et al. Ascorbic acid (vitamin C) and iloprost attenuate the lung injury caused by ischemia/reperfusion of the lower extremities of rats. Ann Vasc Surg 2006; 20:49-55.
30. 30. Kingston R, Kelly CJ, Murray P. The therapeutic role of taurine in ischaemia-reperfusion injury. Curr Pharm Des 2004; 10:2401-2410.
31. 31. Korkmaz A, Kolankaya D. The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats. Ren Fail 2009; 31:36-43.
32. 32. Döşlüoğlu HH, Aktan AO, Yeğen C et al. The cytoprotective effects of verapamil and iloprost (ZK 36374) on ischemia/reperfusion injury of kidneys. Transpl Int 1993; 6:138-142.
33. 33. Erkasap S, Erkasap N, Koken T et al. Effect of leptin on renal ischemia-reperfusion damage in rats. J Physiol Biochem 2004; 60:79-84.
34. 34. Grossini E, Molinari C, Pollesello P et al. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther 2012; 342:376-388.
35. 35. Kucuk A, Kabadere S, Tosun M et al. Protective effects of doxycycline in ischemia/reperfusion injury on kidney. J Physiol Biochem 2009; 65:183-191.
36. 36. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW. Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo. Anesthesiology 2004; 101:1313-1324.
37. 37. Kim M, Kim M, Kim N, D'Agati VD, Emala CW, Sr., Lee HT. Isoflurane mediates protection from renal ischemia-reperfusion injury via sphingosine kinase and sphingosine-1-phosphate-dependent pathways. Am J Physiol Renal Physiol 2007; 293:F1827-1835.
38. 38. Lee HT, Kim M, Jan M, Emala CW. Anti-inflammatory and antinecrotic effects of the volatile anesthetic sevoflurane in kidney proximal tubule cells. Am J Physiol Renal Physiol 2006; 291:F67-78.
39. 39. Urner M, Limbach LK, Herrmann IK et al. Fluorinated groups mediate the immunomodulatory effects of volatile anesthetics in acute cell injury. Am J Respir Cell Mol Biol 2011; 45:617-624.
40. 40. Lee HT, Kim M, Kim J, Kim N, Emala CW. TGF-beta1 release by volatile anesthetics mediates protection against renal proximal tubule cell necrosis. Am J Nephrol 2007; 27:416-424.
41. 41. Zheng Y, Lu H, Huang H. Desflurane Preconditioning Protects Against Renal Ischemia-Reperfusion Injury and Inhibits Inflammation and Oxidative Stress in Rats Through Regulating the Nrf2-Keap1-ARE Signaling Pathway. Drug Des Devel Ther 2020; 14:1351-1362.
42. 42. Zhang Y, Hu F, Wen J et al. Effects of sevoflurane on NF-кB and TNF-α expression in renal ischemia-reperfusion diabetic rats. Inflamm Res 2017; 66:901-910.
43. 43. Zheng B, Zhan Q, Chen J, Xu H, He Z. Sevoflurane pretreatment enhance HIF-2α expression in mice after renal ischemia/reperfusion injury. Int J Clin Exp Pathol 2015; 8:13114-13119.
44. 44. Savran Karadeniz M, Senturk Ciftci H, Tefik T et al. Effects of Different Volatile Anesthetics on Cytokine and Chemokine Production After Ischemia-Reperfusion Injury in Patients Undergoing Living-Donor Kidney Transplant. Exp Clin Transplant 2019; 17:68-74.